New strategy aims to stop bone loss when patients quit osteoporosis drug
NCT ID NCT07281586
Summary
This study is testing a new plan to help people safely stop a long-term osteoporosis drug called denosumab (Prolia). When this drug is stopped suddenly, bones can weaken quickly. Researchers want to see if giving a half-dose of the drug for a short time, along with a different bone-strengthening medicine, can better protect bone density. The trial includes 44 postmenopausal women and men over 50 who have taken denosumab for at least three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital Yunlin Branch
RECRUITINGDouliu, Taiwan, 640, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.